PIK3CA and neoplasm: The alpha-selective PI3K inhibitor alpelisib was also recently approved as a therapeutic option in combination with fulvestrant in MBC patients whose tumours harbour oncogenic alterations of the PIK3CA gene, including patients that have progressed after receiving ET in combination with a CDK4/6 inhibitor [15, 16].